AzTrials
AzTrials

Renal StoneNCT05697341

Ultra Mini Percutaneous Nephrolithotomy VS Stented Extracorporeal Shock Wave Lithotripsy for Stone Management

A study testing Ultra-Mini-PCNL and Stented SWL in people with Renal Stone, run by Ain Shams University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Nephrolithiasis is the third most common disease of the urinary tract. As minimally invasive technologies develop, shock wave lithotripsy (SWL), retrograde intrarenal surgery (RIRS), and percutaneous nephrolithotomy (PCNL) are different surgeries to treat renal stones. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Renal Stone
What is being tested?
Ultra-Mini-PCNL and Stented SWL
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
1 siteEgypt
Study dates
1 Mar 2021to 1 Jun 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • patients between 18 and 60 years
  • complaining of radioopaque renal stones ranging from 10-20 mm.
  • BMI not exceeding 40

Who cannot join

  • radiolucent stones,
  • smaller than 10 mm or larger than 20 mm stones
  • congenital renal anomalies or spinal deformity
  • BMI exceeding 40.
  • Patients with uncorrected bleeding diathesis
  • pregnant females
  • untreated UTI.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Ain Shams University, Faculty of medicine

    Cairo, Abbassia, 1181

Other trials in Egypt

About this study

Official title: A Comparative Study Between Ultra Mini Percutaneous Nephrolithotomy Versus Stented Extracorporeal Shock Wave Lithotripsy for Treatment of Renal Stones in Egypt

Nephrolithiasis is the third most common disease of the urinary tract. As minimally invasive technologies develop, shock wave lithotripsy (SWL), retrograde intrarenal surgery (RIRS), and percutaneous nephrolithotomy (PCNL) are different surgeries to treat renal stones.

Aim of the Study is to compare results, safety and outcome of Ultra mini PCNL versus stented extracorporeal shock wave lithotripsy (SWL) for the management of renal calculi from 10 - 20 mm. Patients were randomized to either Ultra-Mini-Percutaneous nephrolithotomy group or stented SWL group via the closed envelope method. Patient data was collected preoperatively, immediately postoperatively and 2 and 4 weeks postoperatively to assess operative time, hospital stay, complications regarding fever, hematuria and need for blood transfusion, residual stones and need for retreatment.

Read the detailed description

Nephrolithiasis is the third most common disease of the urinary tract, following urinary tract infections and Prostatic diseases. It also has a 1-year recurrence rate of 7% and 10-year recurrence rate of 50%.

Management of renal stones had seen a great shift over the last ten years. The need to find a balance between morbidity and stone clearance is always the milestone of treatment choice. Low risk procedure with high retreatment percentage vs another relatively higher risk procedure with lower retreatment chances.

As minimally invasive technologies develop, shock wave lithotripsy (SWL), retrograde intrarenal surgery (RIRS), and percutaneous nephrolithotomy (PCNL) are different surgeries to treat renal stones. Open, laparoscopic, and robotic surgeries have their place only in highly selected patients.

In the European Association of Urology (EAU) Guidelines on Urolithiasis, PCNL is a treatment of choice (TOC) for renal stones > 20 mm, SWL or RIRS is the first-line therapy for renal stones < 10 mm, and SWL or endourologic treatment (all PCNL and ureteroscopic interventions) can be performed for stones 10-20 mm.

SWL is a minimally invasive intervention with good patient tolerance; it is regarded as the first line treatment for nephrolithiasis < 20 mm in size. Poor clearance of lower calyceal stone fragments due to gravity or unfavorable infundibulopelvic angle limits the efficacy of SWL for treating lower calyceal stones.

flexible ureteroscopy increased quality and performance of upper urinary tract exploration, allowing the treatment the majority of stones at all sites. Experiences with RIRS have revealed higher stone-free rate (SFR) with less risk of renal damage and bleeding. Nevertheless, RIRS is also associated with some disadvantages as the possible need for staged procedures, risk of ureteral injuries and the costs of acquisition and maintenance of the complex endourological instruments and those issues can be possible factors that might have limited the capillary diffusion of this endoscopic procedure.

Percutaneous nephrolithotripsy (24-30F) remains the standard procedure for treating large renal calculi. While achieving high SFR, it also has many drawbacks such as bleeding, postoperative pain, and a long recovery period due to its large access tract, so the mini percutaneous nephrolithotripsy (14-22F) with a smaller tract size came into existence. To reduce renal parenchymal injury associated with standard PCNL, minimally invasive PCNL with a smaller tract size has been developed. Depending on the size of the access tract, minimally invasive PCNL can be classified into Mini-PCNL (14- 22Fr), Ultra-mini-PCNL (11-13Fr).

PCNL carried a significantly higher stone free rate than RIRS, especially for lower calyceal stones (OR=2.65, P=.003), however Mini-PCNL was at the expense of a longer hospital stay and an increased hemoglobin drop.

Although PCNL could exhibit a stone free rate of 93.8%, a global survey revealed that it carried a complication rate of up to 14.5%.

Ulra-mini-PCNL offer a particular advantage for difficult to access calculi, impacted lower pole calculi with an acute infundibular angle or stones in a calyceal diverticulum, with the greater advantage of reduced bleeding.

This study was conducted at Urology department, Faculty of Medicine, Ain Shams University. Inclusion criteria included patients between 18 and 60 years, complaining of radioopaque renal stones ranging from 10-20 mm with BMI not exceeding 40 Exclusion criteria were patients who had radiolucent stones, smaller than 10 mm or larger than 20 mm, with congenital renal anomalies or spinal deformity or BMI exceeding 40. Patients with uncorrected bleeding diathesis or pregnant females or untreated urinary tract infection were also excluded.

In this study patients were recruited from the outpatient urology clinic between March 2021 till March 2022.

Using Power Analysis and Sample Size Software version 15 program for sample size calculation after reviewing results from a previous study (Zhang et al, 2019) we assume a medium effect size difference between the two groups regarding the stone-free rate ( d=0.6), based on these findings sample size of 90 patients (45 per group) achieve 80% power to reject the null hypothesis of zero effect size when the population effect size is 0.60 and the significance level (alpha) is 0.050 using a two-sided z test.

Patients were randomized to either Group A Ultra-Mini-Percutaneous nephrolithotomy group or Group B stented SWL group via the closed envelope method.

Preoperative evaluation including careful history taking, general and local examination, urine analysis, perioperative labs (CBC, bleeding profile, liver and renal functions), Computerized tomography Urinary Tract (CTUT) with Hounsfield unit estimation and Plain X-ray of the urinary tract (KUB).

All patients were given perioperative antibiotic prophylaxis. In The Ultra-Mini-percutaneous nephrolithotomy group, a 5 Fr open-ended ureteral catheter was introduced in the renal pelvis, and a retrograde pyelogram was performed in the Lithotomy position after the induction of general anesthesia. Patients were then repositioned to the prone position. Ultra-mini-PCNLs were done in a prone position by a single consultant. The desired calyx was punctured with a Cook diamond tip puncture needle under fluoroscopy guidance using standard bull's eye technique. Single tract dilatation with One Step Dilator (11Fr), with central channel for guide wires with its Operating Sheath (Storz Dilator and Operating Sheaths for Minimal Invasive PCNL (MIP) XS) under fluoroscopy guidance. Storz Nephroscope for MIP XS / S along with Swiss Lithoclast master pneumatic lithotripter with 1/0.8 mm probe was used for stone fragmentation. Stone fragments are flushed out on rapid removal of the endoscope, due to a 'vortex' effect and with wash through the operating sheath using a 6 Fr. nelaton catheter.

In the stented Extracorporeal ShockWave Lithotripsy (ESWL) group, a 5 Fr open-ended ureteral catheter was introduced in the renal pelvis, and a retrograde pyelogram was performed in the Lithotomy position after the induction of general anaesthesia JJ is applied either 5-26 or 5-28 according to the patient. ESWL was administered with an electromagnetic shockwave lithotripter (Siemens electromagnetic lithotripters devices). Patients were positioned supine with the shock head from the back. Fluoroscopy was used for the localization and monitoring of stone fragmentation. All patients received shocks at a frequency of 60/min. An average of approximately 2500-3000 shocks was targeted in all patients.

Follow up of patients was done postoperative immediately including careful and detailed history taking and examination including pain, fever, sepsis, and hematuria. Serum Hb level, S.creatinine, BUN, Na+, K+

Conditions
Renal Stone
Being tested
Ultra-Mini-PCNL, Stented SWL
Keywords
Nephrolithiasis, Ultra-Mini-PCNL, Stented SWL
Medical subject headings
Nephrolithiasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultra-Mini-PCNLProcedure or surgery

    treatment to extract or disintegrate renal stones

  • Stented SWLProcedure or surgery

    treatment to disintegrate renal stones in the presence of a JJ

Study groups in NCT05697341
Study groupRoleWhat they receive
Ultra-Mini-PCNL Group (A)Active comparatorIn The Ultra-Mini-percutaneous nephrolithotomy group, a 5 Fr open-ended ureteral catheter was introduced and a retrograde pyelogram was performed in the Lithotomy position after the induction of general anesthesia. Patients were then repositioned to the prone position. Ultra-mini-PCNLs were done in a prone position by a single consultant. The desired calyx was punctured with a Cook diamond tip 18G puncture needle under fluoroscopy guidance using standard bull's eye technique. Single tract dilatation with One Step Dilator (11Fr), with central channel for guide wires with its Operating Sheath (Storzz Dilator and Operating Sheaths for MIP XS) under fluoroscopy guidance. Storzz Nephroscope for MIP XS / S along with Swiss Lithoclast master pneumatic lithotripter with 1/0.8 mm probe was used for stone fragmentation. Stone fragments are flushed out on rapid removal of the endoscope, due to a 'vortex' effect and with wash through the operating sheath using a 6 Fr. nelaton catheter.
Receives: Procedure: Ultra-Mini-PCNL
Stented SWL Group (B)Active comparatorIn the stented ESWL group, a 5 Fr open-ended ureteral catheter was introduced in the renal pelvis, and a retrograde pyelogram was performed in the Lithotomy position after the induction of general anathesia. JJ is applied either 5-26 or 5-28 accorging to the patient. Extracorporeal shock wave lithotripsy ESWL was administered with an electromagnetic shockwave lithotripter (Siemens electromagnetic lithotripters devices). Patients were positioned supine with the shock head from the back. Fluoroscopy was used for the localization and monitoring of stone fragmentation. All patients received shocks at a frequency of 60/min. An average of approximately 2500-3000 shocks was targeted in all patients.
Receives: Procedure: Stented SWL

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Stone-free status

    The complete stone clearance or presence of clinically insignificant residual fragments (<4 mm) 2 or 4 weeks after the final procedure was regarded as stone-free

    Measured: at 2 or 4 weeks after ultra-mini-PCNL or stented SWL

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jan 2023
  2. Study start1 Mar 2021
  3. Primary completion1 Mar 2022
  4. Study completion1 Jun 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
90 Patients were enrolled from the outpatient urology clinic of Ain Shams University hospital (Demredash Hospital) randomized to either Group A Ultra-Mini-Percutaneous nephrolithotomy group or Group B stented SWL group via the closed envelope method.
Masking
None (open label)
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05697341
Sponsor's protocol ID
YRS0001
Status last verified
Jan 2023
First submitted
13 Jan 2023
Last updated
25 Jan 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petrik A, Turk C. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015 Apr;67(4):750-63. doi: 10.1016/j.eururo.2014.10.029. Epub 2014 Nov 20.

    PubMed 25454613
  • Kim CH, Chung DY, Rha KH, Lee JY, Lee SH. Effectiveness of Percutaneous Nephrolithotomy, Retrograde Intrarenal Surgery, and Extracorporeal Shock Wave Lithotripsy for Treatment of Renal Stones: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2020 Dec 30;57(1):26. doi: 10.3390/medicina57010026.

    PubMed 33396839
  • Gao XS, Liao BH, Chen YT, Feng SJ, Gao R, Luo DY, Liu JM, Wang KJ. Different Tract Sizes of Miniaturized Percutaneous Nephrolithotomy Versus Retrograde Intrarenal Surgery: A Systematic Review and Meta-Analysis. J Endourol. 2017 Nov;31(11):1101-1110. doi: 10.1089/end.2017.0547. Epub 2017 Oct 30.

    PubMed 28950716
  • Bozzini G, Verze P, Arcaniolo D, Dal Piaz O, Buffi NM, Guazzoni G, Provenzano M, Osmolorskij B, Sanguedolce F, Montanari E, Macchione N, Pummer K, Mirone V, De Sio M, Taverna G. A prospective randomized comparison among SWL, PCNL and RIRS for lower calyceal stones less than 2 cm: a multicenter experience : A better understanding on the treatment options for lower pole stones. World J Urol. 2017 Dec;35(12):1967-1975. doi: 10.1007/s00345-017-2084-7. Epub 2017 Sep 5.

    PubMed 28875295

Questions about this trial

What is this clinical trial studying?

A study testing Ultra-Mini-PCNL and Stented SWL in people with Renal Stone, run by Ain Shams University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Stone-free status (time frame: at 2 or 4 weeks after ultra-mini-PCNL or stented SWL). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05697341, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in